(Q40757462)

23 September 2017

1 reference

title

Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy (English)

1 reference

23 September 2017

S A Spinler

1

1 reference

23 September 2017

M J Cziraky

series ordinal

2

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 March 1994

1 reference

Annals of Pharmacotherapy

23 September 2017

published in

1 reference

23 September 2017

volume

28

1 reference

23 September 2017

issue

3

1 reference

23 September 2017

page(s)

343-351

1 reference

Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Serum Lipids in Angiographically Assessed Coronary Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

The mysteries of lipoprotein(a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Lipoprotein (a). Heterogeneity and biological relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

A potential basis for the thrombotic risks associated with lipoprotein(a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Lipids and endurance physical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein (a) level in familial hypercholesterolemic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Simvastatin in severe hypercholesterolaemia: a placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Probucol protects lipoprotein (a) against oxidative modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800310

10.1177/106002809402800310

21 January 2018

Identifiers

DOI

0 references

1 reference